To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Despite the prevalence of cancer misinformation, exposure to it is not associated with greater fear of cancer recurrence or ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for ...

Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...

Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 ...

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...

The Centres for Disease Control and Prevention in the United States notes that frequent urination "often at night" serves as ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...

-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...